The microbiome in HLA-B27-associated disease: implications for acute anterior uveitis and recommendations for future studies

Trends Microbiol. 2023 Feb;31(2):142-158. doi: 10.1016/j.tim.2022.08.008. Epub 2022 Sep 1.

Abstract

The pathogenesis of human leukocyte antigen (HLA)-B27-associated diseases such as acute anterior uveitis (AAU) and ankylosing spondylitis (AS) remains poorly understood, though Gram-negative bacteria and subclinical bowel inflammation are strongly implicated. Accumulating evidence from animal models and clinical studies supports several hypotheses, including HLA-B27-dependent dysbiosis, altered intestinal permeability, and molecular mimicry. However, the existing literature is hampered by inadequate studies designed to establish causation or uncover the role of viruses and fungi. Moreover, the unique disease model afforded by AAU to study the gut microbiota has been neglected. This review critically evaluates the current literature and prevailing hypotheses on the link between the gut microbiota and HLA-B27-associated disease. We propose a new potential role for HLA-B27-driven altered antibody responses to gut microbiota in disease pathogenesis and outline recommendations for future well-controlled human studies, focusing on AAU.

Trial registration: ClinicalTrials.gov NCT01330901 NCT03726645 NCT03058900.

Keywords: HLA-B27; acute anterior uveitis; gut microbiome; human leukocyte antigens; inflammatory bowel diseases; spondyloarthropathy.

Publication types

  • Review

MeSH terms

  • Acute Disease
  • Animals
  • Gastrointestinal Microbiome*
  • HLA-B27 Antigen / genetics
  • Humans
  • Microbiota*
  • Spondylitis, Ankylosing* / complications
  • Uveitis, Anterior* / complications
  • Uveitis, Anterior* / pathology

Substances

  • HLA-B27 Antigen

Associated data

  • ClinicalTrials.gov/NCT01330901
  • ClinicalTrials.gov/NCT03726645
  • ClinicalTrials.gov/NCT03058900